Merck Receives FDA Approval for Keytruda as Adjuvant Therapy in Hepatocellular Carcinoma

Merck today announced that the FDA has approved KEYTRUDA (pembrolizumab) as adjuvant therapy for the treatment of adults with hepatocellular carcinoma (HCC) who have undergone curative resection or ablation. In the Phase 3 KEYNOTE-937 trial, KEYTRUDA demonstrated a statistically significant improvement in recurrence-free survival compared to placebo. This approval provides HCC patients with a new adjuvant treatment option to reduce the risk of recurrence following curative-intent therapy, addressing a significant unmet medical need in this high-recurrence disease.